Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025 8:01 AM ESTÂ Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch
 MESA open-label extension trial of sevasemten in Becker muscular dystrophy continues to enroll nearly all eligible participants
 Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025
Initiated Phase 1 healthy adult trial of EDG-15400 for future studies in Heart Failure
BOULDER, Colo., Nov. 6, 2025 /PRNewswire/... More
